UNSPSC 51422346: Dichlorisone acetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C23H28Cl2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64FTA4579H, chemically known as 9alpha,11beta-dichloro-17alpha,21-dihydroxypregna-1,4-diene-3,20-dione 21-acetate but more generally known as dichlorisone acetate, which bears US NIH Compound Identifier 6605. Most nations, for tariff and trade purposes, schedule dichlorisone acetate under HS 29372200 and SITC 54153.

As of Q4 2014, DICHLORISONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)CL)CL)C)O.

UNSPSC 51422346 Dichlorisone acetate is a Commodity code that in practice captures pharmaceutical and health-supply procurement by state and local health authorities, though recent state and local solicitations tagged to this code show minimal alignment with the narrow chemical name and instead reflect broader emergency-response and pharmacy-benefit initiatives. Seminole County, Florida solicited naloxone and drug deactivation systems through IFB 60459723LAS, and the Texas Health and Human Services Commission issued RFI HHS0017013 on direct-to-manufacturer pharmacy programs — neither purchase involves dichlorisone acetate specifically, suggesting that the code's application in state and local systems is either miscategorized or serves as a catch-all for pharmaceutical acquisitions that do not map cleanly to narrower commodity codes. The issuing bodies include county health departments and state health agencies, both operating within public-health and opioid-response mandates that drive procurement of emergency medications and pharmacy-benefit infrastructure.

Geographic activity centers on Florida and Texas based on recent postings, with Seminole County's annual procurement of naloxone and deactivation systems reflecting local-government health initiative spending, and the Texas HHS Commission's information-gathering phase signaling state-level interest in direct pharmaceutical contracting. The Seminole County IFB, released in mid-2026, sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: the posted date of June 30, 2026 and due date of July 26, 2023 create an inconsistency in the source); the contract carried a two-year initial term with one-year renewal option and required E-Verify compliance and standard insurance coverage. The Texas RFI, posted April 3, 2026, requested vendor capabilities for direct manufacturer contracts outside traditional pharmacy benefit manager and group purchasing organization channels, signaling exploratory procurement intent rather than immediate award activity. Code activity appears sparse and narrowly tied to emergency-response and state pharmacy-system modernization rather than broad chemical-supply markets.